Literature DB >> 24309016

Modified partial superficial parotidectomy versus conventional superficial parotidectomy improves treatment of pleomorphic adenoma of the parotid gland.

Chao Li1, Yiquan Xu2, Caiyun Zhang3, Chuanzheng Sun4, Yu Chen5, Hongwei Zhao5, Guojun Li6, Jinchuan Fan7, Dapeng Lei8.   

Abstract

BACKGROUND: Surgical treatment of pleomorphic adenoma of the parotid gland remains a subject of major debate. The investigators compared postoperative complications and surgical parameters between modified partial superficial parotidectomy and conventional superficial parotidectomy.
METHODS: Clinical records of 129 patients were reviewed and analyzed for clinical characteristics.
RESULTS: Compared with the conventional superficial parotidectomy group, the modified partial superficial parotidectomy group had significantly lower rates of auricular numbness, Frey's syndrome, and obvious facial asymmetry (all P values <.05). The distance between the primary tumor capsule and satellite nodules ranged from .06 to 8.48 mm, and the greatest distance between the primary tumor capsule and satellite nodules was observed in tumors >4 cm. Furthermore, satellite nodules were more common in tumors >4 cm than in tumors <2 cm or tumors between 2 and 4 cm (all P values <.05).
CONCLUSIONS: Modified partial superficial parotidectomy compares favorably surgically and clinically with conventional superficial parotidectomy in certain patients.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Frey's syndrome; Parotid gland; Parotidectomy; Pleomorphic adenoma; Postoperative complications; Surgical margin

Mesh:

Year:  2013        PMID: 24309016     DOI: 10.1016/j.amjsurg.2013.08.036

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  8 in total

1.  Classification of parotidectomy: a proposed modification to the European Salivary Gland Society classification system.

Authors:  Wai Keat Wong; Subhaschandra Shetty
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-05-11       Impact factor: 2.503

2.  Primary repair and reconstruction of tumor defects in parotid masseter region: a report of 58 cases.

Authors:  Yong-Cong Cai; Chun-Yan Shui; Chao Li; Rong-Hao Sun; Yu-Qiu Zhou; Wei Liu; Xu Wang; Dinfen Zeng; Jian Jiang; Guiquan Zhu; Wei Wang; Zhenghua Jiang; Zhenqi Tang
Journal:  Gland Surg       Date:  2019-08

Review 3.  Graft interposition for preventing Frey's syndrome in patients undergoing parotidectomy.

Authors:  Li Ye; Yubin Cao; Wenbin Yang; Fanglong Wu; Jie Lin; Longjiang Li; Chunjie Li
Journal:  Cochrane Database Syst Rev       Date:  2019-10-03

Review 4.  Why Do Parotid Pleomorphic Adenomas Recur? A Systematic Review of Pathological and Surgical Variables.

Authors:  Pavel Dulguerov; Jelena Todic; Marc Pusztaszeri; Naif H Alotaibi
Journal:  Front Surg       Date:  2017-05-15

5.  Complications after superficial parotidectomy for pleomorphic adenoma.

Authors:  P Infante-Cossio; E Gonzalez-Cardero; A Garcia-Perla-Garcia; E Montes-Latorre; J-L Gutierrez-Perez; V-E Prats-Golczer
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2018-07-01

6.  Head & neck acinar cell carcinoma: a population-based study using the seer registry.

Authors:  Feiluore Yibulayin; Lei Feng; Meng Wang; Meng-Meng Lu; Yuan Luo; Hui Liu; Zhi-Cheng Yang; Alimujiang Wushou
Journal:  BMC Cancer       Date:  2020-07-08       Impact factor: 4.430

7.  Salivary Gland Pleomorphic Adenomas Presenting With Extremely Varied Clinical Courses. A Single Institution Case-Control Study.

Authors:  Krzysztof Piwowarczyk; Ewelina Bartkowiak; Paweł Kosikowski; Jadzia Tin-Tsen Chou; Małgorzata Wierzbicka
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

8.  Antegrade versus retrograde facial nerve dissection in benign parotid surgery: Is there a difference in postoperative outcomes? A meta-analysis.

Authors:  Mubarak Ahmed Mashrah; Taghrid Ahmed Al-Dhohrah; Fahmi Ahmed Al-Zubeiry; Lingjian Yan; Faez Saleh Al-Hamed; Xiaopeng Zhao; Chaobin Pan
Journal:  PLoS One       Date:  2018-10-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.